Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorSharma, Ritu S.
dc.contributor.authorHarrison, David J.
dc.contributor.authorKisielewski, Dorothy
dc.contributor.authorCassidy, Diane M.
dc.contributor.authorMcNeilly, Alison D.
dc.contributor.authorGallagher, Jennifer R.
dc.contributor.authorWalsh, Shaun V.
dc.contributor.authorHonda, Tadashi
dc.contributor.authorMcCrimmon, Rory J.
dc.contributor.authorDinkova-Kostova, Albena T.
dc.contributor.authorAshford, Michael L.J.
dc.contributor.authorDillon, John F.
dc.contributor.authorHayes, John D.
dc.date.accessioned2018-02-26T16:30:06Z
dc.date.available2018-02-26T16:30:06Z
dc.date.issued2017-12-13
dc.identifier.citationSharma , R S , Harrison , D J , Kisielewski , D , Cassidy , D M , McNeilly , A D , Gallagher , J R , Walsh , S V , Honda , T , McCrimmon , R J , Dinkova-Kostova , A T , Ashford , M L J , Dillon , J F & Hayes , J D 2017 , ' Experimental nonalcoholic steatohepatitis and liver fibrosis are ameliorated by pharmacological activation of Nrf2 (NF-E2-related factor 2) ' , Cellular and Molecular Gastroenterology and Hepatology , vol. 5 , no. 3 , pp. 367-398 . https://doi.org/10.1016/j.jcmgh.2017.11.016en
dc.identifier.issn2352-345X
dc.identifier.otherPURE: 251636943
dc.identifier.otherPURE UUID: fdf975ca-1cfa-4daa-b33c-17bb2ea6fb57
dc.identifier.otherRIS: urn:1E3B330D33F9A577275B1C03B990914D
dc.identifier.otherRIS: urn:1E3B330D33F9A577275B1C03B990914D
dc.identifier.otherScopus: 85043604839
dc.identifier.otherORCID: /0000-0001-9041-9988/work/64034337
dc.identifier.otherWOS: 000428840500014
dc.identifier.urihttp://hdl.handle.net/10023/12789
dc.descriptionFunding: Supported by grants MR/J001465/1 (JDH, MLJA, JFD and RJMcC) and MR/N009851/1 (JDH, MLJA, ATD-K and DJH) from the Medical Research Council of the UK and grants from Stony Brook Foundation and Reata Pharmaceuticals, Inc. (TH)en
dc.description.abstractBackground & Aims:  Nonalcoholic steatohepatitis (NASH) is associated with oxidative stress. We surmised that pharmacological activation of NF-E2 p45-related factor 2 (Nrf2) using the acetylenic tricyclic bis(cyano-enone) TBE-31 would suppress NASH because Nrf2 is a transcriptional master regulator of intracellular redox homeostasis. Methods:  Nrf2+/+ and Nrf2-/- C57BL/6 mice were fed a high-fat plus fructose (HFFr) or regular chow (RC) diet for 16 weeks or 30 weeks, and then treated for the final 6 weeks, whilst still being fed the same HFFr or RC diets, with either TBE-31 or DMSO vehicle control. Measures of whole body glucose homeostasis, histological assessment of liver, and biochemical and molecular measurements of steatosis, endoplasmic reticulum (ER) stress, inflammation, apoptosis, fibrosis and oxidative stress were performed in livers from these animals. Results:  TBE-31−treatment reversed insulin resistance in HFFr-fed wild-type mice, but not in HFFr-fed Nrf2-null mice. TBE-31−treatment of HFFr-fed wild-type mice substantially decreased liver steatosis and expression of lipid synthesis genes, whilst increasing hepatic expression of fatty acid oxidation and lipoprotein assembly genes. Also, TBE-31−treatment decreased ER stress, expression of inflammation genes, and markers of apoptosis, fibrosis and oxidative stress in the livers of HFFr-fed wild-type mice. By comparison, TBE-31 did not decrease steatosis, ER stress, lipogenesis, inflammation, fibrosis or oxidative stress in livers of HFFr-fed Nrf2-null mice. Conclusions:  Pharmacological activation of Nrf2 in mice that had already been rendered obese and insulin resistant reversed insulin resistance, suppressed hepatic steatosis, and mitigated against NASH and liver fibrosis, effects that we principally attribute to inhibition of ER, inflammatory and oxidative stress.
dc.format.extent32
dc.language.isoeng
dc.relation.ispartofCellular and Molecular Gastroenterology and Hepatologyen
dc.rights© 2018 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).en
dc.subjectNASHen
dc.subjectNrf2en
dc.subjectTBE-31en
dc.subjectRM Therapeutics. Pharmacologyen
dc.subjectQH301 Biologyen
dc.subjectNDASen
dc.subject.lccRMen
dc.subject.lccQH301en
dc.titleExperimental nonalcoholic steatohepatitis and liver fibrosis are ameliorated by pharmacological activation of Nrf2 (NF-E2-related factor 2)en
dc.typeJournal articleen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews.School of Medicineen
dc.contributor.institutionUniversity of St Andrews.Cellular Medicine Divisionen
dc.identifier.doihttps://doi.org/10.1016/j.jcmgh.2017.11.016
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record